CTによる間質性肺疾患の定量的評価
視覚スコアおよび肺濃度測定法を使用した間質性肺疾患の CT 定量的評価および肺機能検査との相関
Interstitial lung disease (ILD) refers to a broad category of heterogeneous lung diseases with different etiologies and features characterized by inflammation and fibrosis of the lung parenchyma and manifested as exertional dyspnea, interstitial patterns on high resolution computed tomography (HRCT), and abnormal pulmonary function tests (PFTs) The aim of this study is to investigate is there any correlation between changes seen in the lung parenchyma by HRCT and the pulmonary functions of the patients.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This study will utilize a cross-sectional prospective study design in a single institution to investigate the correlation between CT chest findings including lung densitometry and pulmonary function test results in patients with ILD.
The study population will consist of consecutive patients diagnosed with ILD recruited from the pulmonary clinic or inpatient service.
High resolution CT chest and pulmonary function tests are routine diagnostic tests used for diagnosis of interstitial lung disease .
both tests are non invasive for the patient and will be acquired for all patients and then their results will be correlated.
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Ramy M Ahmed, MD
- 電話番号:+201153070865
- メール:ramycolor@aun.edu.eg
研究場所
-
-
Asyut Governorate
-
Asyut、Asyut Governorate、エジプト、71515
- Assiut University Hospital
-
コンタクト:
- Ramy M Ahmed, MD
- 電話番号:01153070865
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The study population will consist of consecutive patients diagnosed with ILD recruited from the pulmonary clinic or inpatient service. The diagnosis of ILD will be based on American Thoracic Society/European Respiratory Society (ATS/ERS) classification system for ILD.
説明
Inclusion Criteria:
- Diagnosis of ILD (based on clinical, radiological, and pulmonary function criteria +/- histopathological criteria).
- Availability of CT chest DICOM images and pulmonary function test results (within a 2-weeks period from each other).
Exclusion Criteria:
- Pregnancy
- Pulmonary edema.
- Primary pulmonary hypertension;
- Chronic obstructive pulmonary disease
- Congestive heart failure
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:CASE_ONLY
- 時間の展望:PROSPECTIVE
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
CT visual Warrick score (measured by points)
時間枠:baseline
|
Warrick score is calculated as follow : A point value will be given to each abnormality i.e ground-glass appearance (areas of hazy opacity in the lung that do not obscure the underlying bronchial structures) = 1, irregular pleural margins = 2, septal/subpleural lines = 3, honeycombing (usually 3-10 mm in diameter and have thick walls) = 4, and subpleural cysts = 5. In each patient, the "severity of disease" score will be obtained by adding single point values (maximal severity score 15). An "extent of disease" score is obtained by counting the number of bronchopulmonary segments involved for each abnormality as follows ; one to three segments scored as 1, four to nine segments scored as 2, and more than nine segments scored as 3 (maximal extent score 15). The severity and extent of disease will be then calculated as the total Warrick score (range from 0 to 30) |
baseline
|
|
Total lung volume, Volume of lung occupied by low attenuation areas, Volume of lung occupied by high attenuation areas, Volume of normal lung areas and volume of consolidation areas
時間枠:baseline
|
Total lung volume , volume of the lung occupied by low attenuation areas (attenuation values from -1024 to -950 HU; representing emphysema), volume of normally attenuated lung (from -949 to -700 HU; corresponds to healthy lung tissue) and volume of the lung occupied by high attenuation areas (between - 699 and - 250 HU) ; it represents the lung parts which are more dense than healthy lung); volume of lung with density from -249 to +40 HU, this group corresponds to areas with further increase in density, including the semi-consolidation and consolidation. |
baseline
|
|
Percentage of the lung occupied by low attenuation areas, percentage of normal lung, percentage of the lung occupied by high attenuation areas and percentage of consolidation areas.
時間枠:baseline
|
Percentage of the lung occupied by low attenuation areas (attenuation values from -1024 to -950 HU), percentage of normal lung (from -949 to -700 HU), percentage of the lung occupied by high attenuation areas (between - 699 and - 250 HU) and percentage of consolidation areas (from -249 to +40 HU) in each lung and in each lobe. |
baseline
|
|
Mean lung density of each lung, both lungs and every lobe in Hounsfield unit (HU)
時間枠:baseline
|
Mean lung density of each lung , both lungs and each lung lobe (e.g., upper, middle, and lower lobes) will be measured in Hounsfield unit (HU). |
baseline
|
|
Forced vital capacity (FVC)
時間枠:baseline
|
Forced vital capacity (FVC) will be measures using spirometer and expressed as percentage. |
baseline
|
|
Forced expiratory volume in 1 second (FEV1)
時間枠:baseline
|
Forced expiratory volume in 1 second (FEV1) |
baseline
|
|
FEV1/FVC ratio
時間枠:baseline
|
FEV1/FVC ratio will be measures |
baseline
|
|
O2 saturation
時間枠:baseline
|
O2 saturation is measured in percentage (SpO2) using pulse oximeter |
baseline
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Ramy M Ahmed, MD、Assiut University
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。